Carregant...

Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)–positive breast cancer is highly aggressive and has higher risk of recurrence than HER2-negative cancer. With few treatment options available, new drug targets specific for HER2-positive breast cancer are needed. METHODS: We conducted a pha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shim, Joong Sup, Rao, Rajini, Beebe, Kristin, Neckers, Len, Han, Inkyu, Nahta, Rita, Liu, Jun O.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3472971/
https://ncbi.nlm.nih.gov/pubmed/23042933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djs396
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!